Evolution of the Umbilical Cord Blood Proteome Across Gestational Development 1

2

- Leena B. Mithal¹, Nicola Lancki², Ted Ling-Hu^{3,4}, Young Ah Goo⁵, Sebastian Otero¹, Nathaniel J. Rhodes^{6,7,8}, Byoung-Kyu Cho⁵, William A. Grobman⁹, Judd F. Hultquist^{3,4}, Denise Scholtens², Karen G. Mestan¹⁰, Patrick C. Seed¹ 4 5
- ¹ Department of Pediatrics, Division of Infectious Diseases, Ann & Robert H. Lurie Children's 6
- Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 7
- ² Department of Preventive Medicine, Division of Biostatistics, Northwestern University Feinberg 8 9 School of Medicine, Chicago, IL, USA.
- 10 ³Department of Medicine, Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 11
- ⁴Center for Pathogen Genomics and Microbial Evolution, Havey Institute for Global Health, 12
- 13 Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- ⁵ Mass Spectrometry Technology Access Center at McDonnell Genome Institute (MTAC@MGI), 14
- Washington University in Saint Louis School of Medicine, MO, USA. 15
- 16 ⁶ Department of Pharmacy Practice, Midwestern University, College of Pharmacy, Downers Grove, IL, USA. 17
- ⁷ Pharmacometrics Center of Excellence, Midwestern University, Downers Grove, IL, USA. 18
- ⁸ Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA. 19
- ⁹ Department of Obstetrics and Gynecology, Ohio State University, Columbus, OH, USA. 20
- ¹⁰ Department of Pediatrics, Division of Neonatology, University of California San Diego, CA, USA. 21
- 22
- 23 * Correspondence:
- 24 Leena B. Mithal, MD MSCI
- 25 lmithal@luriechildrens.org
- Keywords: cord blood, proteomics, neonatal immunology, prematurity, immune development, 26
- biomarker development 27
- 28
- 29 **Abstract:**
- 30 Neonatal health is dependent on early risk stratification, diagnosis, and timely management of
- 31 potentially devastating conditions, particularly in the setting of prematurity. Many of these conditions
- 32 are poorly predicted in real-time by clinical data and current diagnostics. Umbilical cord blood may
- 33 represent a novel source of molecular signatures that provides a window into the state of the fetus at
- birth. In this study, we comprehensively characterized the cord blood proteome of infants born 34

- 35 between 24 to 42 weeks using untargeted mass spectrometry and functional enrichment analysis. We
- 36 determined that the cord blood proteome at birth varies significantly across gestational development.
- 37 Proteins that function in structural development and growth (e.g., extracellular matrix organization,
- 38 lipid particle remodeling, and blood vessel development) are more abundant earlier in gestation. In
- 39 later gestations, proteins with increased abundance are in immune response and inflammatory
- 40 pathways, including complements and calcium-binding proteins. Furthermore, these data contribute
- 41 to the knowledge of the physiologic state of neonates across gestational age, which is crucial to
- 42 understand as we strive to best support postnatal development in preterm infants, determine
- 43 mechanisms of pathology causing adverse health outcomes, and develop cord blood biomarkers to
- 44 help tailor our diagnosis and therapeutics for critical neonatal conditions.

45 Manuscript text:

46 Introduction

- 47 Neonatal health is dependent on early risk stratification, diagnosis, and timely management of many
- 48 potentially devastating conditions. Preterm infants are at increased risk of prematurity-related
- 49 complications, including: early-onset sepsis, chronic lung disease, intraventricular hemorrhage,
- 50 necrotizing enterocolitis, and neurodevelopmental impairment.¹⁻³ Many of these conditions are
- 51 poorly predicted in real-time by clinical data, including currently available diagnostic testing. Thus,
- 52 biomarkers have been sought to aid early and targeted treatment and prognosis for these conditions.
- 53 Umbilical cord blood may represent a novel source of molecular signatures that provides a window
- 54 into the state of the fetus at birth. Umbilical cord blood inflammatory markers have been studied as
- 55 diagnostic indicators of early-onset sepsis⁴⁻⁶. Specific cord blood cytokines have been identified as
- 56 predictors or correlates of retinopathy of prematurity⁷, atopic disease⁸, infantile hemangioma⁹,
- 57 placental histopathology¹⁰, and more⁴. However, few of these cord blood biomarkers have been
- 58 translated into diagnostic tools in clinical practice.
- 59 "Omics" methodologies have been previously used to profile amniotic fluid and infant blood to
- 60 predict pre-eclampsia, preterm birth, and late-onset sepsis^{11,12}. Mass spectrometry (MS)-based
- 61 proteomics approaches have emerged as a particularly powerful technology for the comprehensive
- 62 profiling of proteins comprising the plasma microenvironment¹³. For example, longitudinal profiling
- 63 of postnatal proteomic changes has provided insights into the development of the immune system
- 64 over the first weeks to months of life¹⁴. Untargeted proteomic analyses furthermore provide an
- 65 unbiased approach to biomarkers discovery by removing the need to identify proteins of interest a
- 66 *priori*.¹⁵
- 67 Proteomic profiling of neonatal cord blood provides a molecular snapshot at variable timepoints
- 68 throughout neonatal development that could be used to reveal the underlying cellular processes
- 69 occurring at birth, readiness for postnatal life, and for the identification of biomarkers specific to
- 70 different disease states and prematurity-related complications.
- 71 While proteomic profiling of cord blood has demonstrated immunologic differences between preterm
- and term infants¹⁶, prior research has lacked inclusion of preterm infants across the continuum of
- 73 gestational age and consideration of key perinatal characteristics such as the route of delivery,
- 74 preeclampsia, intraamniotic infection, and neonatal sepsis that are likely to affect protein abundance.
- 75 In this study, we have comprehensively characterized the cord blood proteome from infants born
- 76 between 25 to 42 weeks using MS to provide a benchmark of normative cord blood proteomic profile
- and examine proteome differences across the developmental range of gestational ages.
- 78

79 Methods

- 80 Study cohort and specimen collection
- 81 We utilized archived cord blood plasma from an ongoing prospective study of infants born at
- 82 Northwestern Prentice Women's Hospital between 2008-2019. Parents were consented prior to or
- 83 after birth; cord blood was centrifuged at 3000 rpm for 10 minutes and was separated into aliquots
- 84 stored at -80 degrees Celsius until use. Samples in this investigation were selected from the

- 85 biorepository based on gestational age and the absence of presumed or proven early onset neonatal
- 86 sepsis (i.e., the infant received no antibiotic treatment course for sepsis within the first 72 hours of
- 87 life and had no positive microbiologic sterile site cultures). A total of 150 infants were frequency
- 88 matched within each gestational age (GA) category (epochs: 25-28 weeks, 29-32 weeks, 33-36
- 89 weeks, 37-42 weeks) with approximately equal numbers by sex, route of delivery (vaginal delivery 90
- vs. caesarean delivery with or without labor), and reason for preterm birth (maternal indication such
- 91 as preeclampsia vs. fetal/pregnancy indication such as spontaneous preterm labor or preterm 92 premature rupture of membranes). Clinical data including birth weight and intraamniotic infection
- 93 were collected from the electronic medical record. This study was approved by the Institutional
- 94 Review Boards of Northwestern University (STU00201858) and Lurie Children's Hospital (IRB
- 95 2018-2145). Parental informed consent was obtained for use of clinical data and infant cord blood
- 96 samples. All research activities were performed in accordance with the Declaration of Helsinki.
- 97 Mass spectrometry sample preparation and analysis
- 98 Samples were thawed on ice and 20µl of plasma was utilized for study. Protein concentrations were 99
- determined using the Bicinchoninic Acid (BCA) method; untargeted mass spectrometry-based 100 proteomic analysis was applied to 600 µg of extracted protein from each plasma sample. Samples
- 101 were first depleted of fourteen known highly abundant proteins (Albumin, IgA, IgD, IgE, IgG, IgG
- 102 (Light chains), IgM, Alpha-1-acid glycoprotein, Alpha-1-antitrypsin, Alpha-2-macroglobulin,
- 103 Apolipoprotein A1, Fibrinogen, Haptoglobin, and Transferrin) using the Top 14 Abundant Protein
- 104 Depletion Spin Columns (Thermo Scientific, Rockford, IL, USA). Remaining proteins were purified
- 105 by acetone/TCA precipitation, reduced, alkylated, and digested with trypsin. Digested peptides were
- 106 desalted on C18 columns (Thermo Scientific, Rockford, IL, USA) and eluted in 80% acetonitrile in
- 107 0.1% formic acid. Peptides were reconstituted with 0.1% formic acid in water and injected onto the
- 108 in-house C18 trap column (3 cm length, 150 µm inner diameter, 3 µm particle size) coupled with an
- 109 analytical C18 column (10.5 cm length, 75 um inner diameter, 2 um particle size, PicoChip).
- 110 Samples were separated using a linear gradient from 5% ACN/0.1% formic acid to 40% ACN/0.1%
- 111 formic acid over 120 minutes using an UltiMate 3000 Rapid Separation nanoLC coupled to a
- 112 Orbitrap Elite Mass Spectrometer (Thermo Fisher Scientific Inc, San Jose, CA). The full scans were
- 113 acquired from 400-2000m/z at 60,000 resolving power and automatic gain control (AGC) set to
- 114 1×10^{6} . The top fifteen most abundant precursor ions in each full scan were selected for
- 115 fragmentation. Precursors were selected with an isolation width of 1 Da and fragmented by collision-
- 116 induced dissociation (CID) at 35% normalized collision energy. Previously selected ions were
- 117 dynamically excluded from re-selection for 58 seconds.
- 118 Samples were analyzed in duplicate, in a specified run order, across four batches. Samples were
- 119 randomly assigned to batches using a stratified sampling approach to achieve balance on gestational
- 120 age and other clinical characteristics (sex, type of delivery). A representative "pooled control,"
- 121 including samples representing the full spectrum of the cohort, was used as an "internal standard"
- 122 and run multiple times in each batch. Within each batch, the run order for samples and controls was
- determined by simple random sampling. MS raw files were analyzed with MaxQuant software 123
- (version 1.6.0.16).¹⁷ MS/MS-based peptide identification was carried out against the SwissProt 124 human database with the Andromeda search engine in MaxQuant¹⁸ using a target-decoy approach to
- 125 identify peptides and proteins at an FDR <1%. For LFO, the MaxLFO algorithm was used as part of
- 126 the MaxQuant environment.¹⁹ The following modifications were set as search parameters: trypsin 127
- 128 digestion cleavage after K or R (except when followed by P), 2 allowed missed cleavage sites,
- 129 carbamidomethylated cysteine (static modification), and oxidized methionine, protein N-term
- 130 acetylation (variable modification). Search results were validated with peptide and protein FDR, both

131 at 0.01. Transformed (log₂) LFQ values were used for all statistical analyses. The mass spectrometry

132 proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner

repository with the dataset identifier PXD051974.

134 Proteomics data normalization

Boxplots representing the median and first and third quartiles were used to visualize the distribution of protein concentration among all proteins in pooled controls and identify the presence of any batch

- effects. To correct for batch effects demonstrated, batch normalization was conducted as follows.
- 138 Proteins that were detected in only one batch were excluded. Using the pooled control samples, the
- average difference in $\log_2 LFQ$ value relative to the first batch was estimated using a linear
- regression model. Briefly, a beta coefficient for each batch was estimated using linear regression with
- batch one serving as the referent. The average protein difference from the first batch was then
- subtracted from the $\log_2 LFQ$ value of each batch to determine the normalized $\log_2 LFQ$ value.
- 143 Visual inspection of post-normalization protein levels by batch was used to determine the adequacy
- 144 of the normalization procedure. The batch normalized protein abundance for each sample was
- 145 averaged across each technical replicate for subsequent inter-patient analyses. If a protein was only
- 146 detected in one of the replicates, the value of the batch normalized detected protein from the single
- 147 replicate was used for analyses.

148 Differential protein abundance determination

- 149 Separate linear regression models were used to examine the association between protein abundance
- and GA (unadjusted and adjusted for sex, labor, route of delivery, and preeclampsia). The response
- 151 variable for each model was the batch normalized value \log_2 transformed protein level for the given
- 152 protein. Proteins were included in adjusted models if found in more than one sex, delivery category,
- and preeclampsia category. The primary explanatory variable of interest was GA. Scatter plots were
- examined to determine whether GA demonstrated a linear or nonlinear association (e.g., using splines
- 155 or quadratic terms) with protein level. The relationships between GA and protein abundance, in
- 156 general, appeared linear across proteins, so a linear term for GA was included in models. There were
- seven sets of twins among the 150 controls. One twin from a pair was randomly selected to be
- 158 included in the models (n=143). To control Type 1 error rate, P-values were adjusted for multiple
- testing using the Benjamini-Hochberg False Discovery Rate (FDR) method, and associations with 160 EDR edimeted Bushage (0.05 many specification line) z^{20}
- 160 FDR-adjusted P values < 0.05 were considered statistically significant²⁰.
- 161 <u>Functional enrichment and visualization</u>
- 162 The relative expression abundance of all proteins that changes significantly over gestational age was
- 163 visualized in a heat map. The batch normalized protein values were z-score normalized by
- subtracting the relative protein abundance within a given specimen by the mean abundance across all
- specimens in which the protein was detected and then dividing by standard deviation. Proteins that
- were undetected in more than 50% of specimens were excluded from visualization. Z-score
- 167 normalized values were visualized in a heatmap using the *clustermap* function in the *seaborn* (v
- 168 0.11.1) package within the python (v 3.8.8) environment with specimens ordered left to right by GA
- and proteins clustered by z-score profile from top to bottom. The *clustermap* function uses
- 170 hierarchical clustering with average linkage and Euclidean distance.
- 171 Functional enrichment analysis of the proteins found to be significantly increased or decreased in
- abundance was performed using MetaScape v3.5

- 173 (<u>https://metascape.org/gp/index.html#/main/step1</u>)²¹. UniProt IDs were used as unique identifiers;
- two isoforms of APOB (P04114), PLG (P00747), and FGA (P02671) were consolidated and
- immunoglobulins were excluded (P0DOX5, P0DOX7, P0DOY3, and P01859) for final analysis of
- 176 64 proteins. All proteins detected in the overall proteomic dataset (n = 465) were set as the
- background gene set before enrichment. Protein-protein interaction networks were visualized using
- 178 STRING v11.5 (<u>https://string-db.org/</u>)²². Network visualization was limited to physical subnetworks
- based on experiment and database active interaction sources with a 0.15 minimum interaction score
- 180 required. Nodes were colored by an increase or decrease in abundance with edge width reflective of
- protein interaction confidence score. Proteins contributing to significantly enriched pathways were
- 182 annotated with colored boxes.
- 183
- 184 **Results**
- 185 Patient demographics

186 The distribution of GA and associated clinical/demographic details for the 150 infants included in

187 this study are displayed in **Table 1**. The mean GA across all infants was 33.2 weeks (standard

188 deviation 4.5, range 25.9-41.4). 17 infants (11%) were 25-28 weeks, 43 (29%) were 29-32 weeks, 50

189 (33%) were 33-36 weeks, and 40 (27%) were 37 weeks and greater. 77 (51%) of the infants were

female. 34 (23%) infants were born to women with preeclampsia. 44 (29%) infants were from 22

individuals with multiple gestations, all of whom were born at less than 37 weeks GA. Only one

192 infant was born to an individual who had clinical chorioamnionitis.

193 Differential protein abundance across GA

194 The total BCA, representative of protein abundance, is positively correlated with GA (Figure 1). Of 195 the 465 unique proteins identified in control plasma samples, 391 were included in the adjusted 196 regression models (adjusted for sex, preeclampsia, and delivery route). Proteins were excluded from 197 adjusted multivariable regression models if they were only found in one group of the covariate categories (for example found in only male infants). Gestational age was associated with protein 198 199 abundance in 70 proteins with FDR-adjusted P-value <0.05 (Supplemental Table 1). To visualize 200 each protein's change over GA, the normalized protein abundance in each specimen was plotted 201 relative to GA of the infant (Figure 2). The slope ('beta' value) of the linear fitted model for each 202 protein is provided in **Supplemental Table 1.** Representative plots in **Figure 2** demonstrate 203 examples of proteins with positive (e.g., plasminogen; Figure 2A) and negative (e.g., alpha-204 fetoprotein; Figure 2B) correlation between protein abundance and GA. These changes are 205 summarized in a volcano plot (**Figure 3**) depicting the \log_{10} of the FDR-adjusted P-values and the 206 associated betas from linear regression models. Proteins such as alpha-fetoprotein, collagen alpha-207 1(V) chain, and basement membrane-specific heparan sulfate proteoglycan core protein are highly 208 abundant earlier in gestational development while many immunologically active proteins are more 209 abundant later, including IgG-1 chain C region, complement C1q subunit C, and protein S100-A9, a calcium- and zinc-binding protein which plays a prominent role in the regulation of inflammatory 210

- 211 response (all aforementioned proteins with p<0.0001).
- 212 <u>Visualization and pathway analysis</u>
- 213 To better visualize the differences in protein levels across GA, we plotted a heatmap of the

214 normalized protein levels for each significantly changing protein identified above in each specimen

215 ordered along the x-axis by GA (Figure 4A). Proteins without detectable levels in more than 50% of

specimens (n = 15) were excluded from visualization and hierarchical clustering was used to group

proteins by similarity in abundance trends over GA. This highlights several distinct groups of
 proteins where levels change over time. For example, COL5A1, CD14, HSPG2, OSOX1, FCGBP

- seem to be abundant in early GA, but decrease as GA increases. This trend is also apparent in the
- cluster located at the bottom half of the heatmap that includes CD109, COL1AI, APOC3, APOE,
- TGFBI, AFP, AGT, APOB, LUM, SERPINA1, B2M, FGA, THBS4, F13A1 and SERPINA5.
- However, several proteins also follow the opposite trend with lower abundance early and higher
- abundance late, including HBA1, HBB, HPX, IGFALS, CP, AFM, SERPINF2, SERPIND1, A2M,
- ATRN, PGLYRP2, IGHG1, C7, ITIH1, PLG, F2, SERPINC1, C1QC and C1QA.
- 225 Functional enrichment analysis was performed for those proteins found to be significantly decreased
- in relative abundance (n = 29, Figure 4B) or increased in abundance (n = 34, Figure 4C) with

increasing GA (7 identifiers did not map back to unique proteins and were excluded from analysis,

see **Methods**). Proteins that decreased in abundance were enriched for eight pathways: NABA core

229 matrisome, extracellular matrix organization, lipid particle remodeling, smooth muscle proliferation,

- blood vessel development, glycosaminoglycan metabolism, insulin-like growth factor regulation, and
- amyloid fiber formation. These enriched protein sets include several components of known protein
- complexes. For example, the proteoglycan LUM and the collagen proteins COL5A1 and COL1AI
- form high confidence protein interactions and are all associated with extracellular matrix
- organization pathways. Likewise, CETP, APOC3, APOB, and APOE are known to interact and play
 critical roles in lipid particle remodeling. Several factors implicated in insulin-like growth factor
- regulation were also decreased, including SERPINF2, SERPIND1, FGA, and SERPINA5.

237 More proteins were found to increase in abundance over GA than decrease. However, these were

associated with a narrower set of pathways, specifically: protein nitrosylation, metal ion homeostasis,

humoral immune response, NABA core matrisome, and positive regulation of cell death. One well-

- 240 known transition that occurs in the serum throughout development is the swapping of hemoglobin
- subunits from γ -globin in neonates to β -globin and δ -globin gene expression in pediatric and adult
- patients²³. Consistent with this transition, we see increased abundance of β-globin (HBB) and δ-
- globin (HBD), as well as α -globin (HBA2). We additionally see the increased abundance of several proteins associated with the immune response, including several complement proteins (C1QA,
- 244 proteins associated with the infinute response, including several complement proteins (C1QA, 245 C1QC, C7, CFP, and C8G) and several S100 calcium binding proteins (S100A9, S100A12, and
- 245 CTQC, C7, CFF, and C8G) and several \$100 calcium binding proteins (\$100A9, \$100A12, and 246 S100A8). Notably, several immunoglobulins were also increased over the course of GA (specifically
- kappa light chain, lambda light chain, and gamma heavy chains), though these are not visualized
- 248
- 249

250 Discussion

here.

251 Our data demonstrate that the abundance of several cord blood proteins varies significantly across

GA. Proteins that function in structural development and growth, including extracellular matrix

253 organization, lipid particle remodeling, blood vessel development, and insulin-like growth factor

regulation, are more abundant earlier in gestation. Later in gestation, proteins involved in immune

response pathways, including complements, and calcium-binding proteins involved in inflammation

are higher in abundance. These data highlight the differences in immunologic state across GA and

- 257 provide insights into the higher risk of invasive infections among preterm infants. Furthermore, these
- 258 data contribute to the knowledge of the physiologic state of neonates across GA, which is crucial to

259 understand as we: 1) strive to emulate the *in utero* environment to best support the developmental

- 260 process of those born preterm, 2) understand mechanisms of pathology that cause adverse health 261 outcomes for preterm infants, and 3) develop cord blood markers for neonatal disease conditions that
- 262 can predict and help tailor medical management.

263 In a 2021 review of proteomic studies that attempted to identify biomarkers for prematurity-related

- diseases, Letunica et al. determined that only 13% of studies investigated cord blood even though 264 cord blood is a readily available specimen at birth.¹¹ Suski *et al.* investigated the cord blood proteome
- 265 of preterm infants in three GA groups (<=26 weeks, 27-28 weeks, and 29-30 weeks) and compared 266
- them to the proteomes of a full term control group. They reported differences in inflammatory, 267
- 268 immunomodulation, coagulation, and complement systems in preterm versus term infants.¹⁶
- Specifically, they found that preterm infants had decreased levels of anti-inflammatory proteins (e.g., 269
- 270 orsomucoid isoforms) and B-cell mediated immunity markers, and increased abundance of
- 271 inflammatory proteins such as leucine-rich alpha-2-glycoprotein (LRG1) and complement activation
- 272 cascades, a finding that complements our results of lower proteins related to humoral immunity at
- 273 earlier GA.

274 However, the authors also suggest an increase in inflammatory mediators in preterm infants, whereas

275 out results showed increased inflammatory and immune response proteins and complement

276 components later in gestational age. Our pathway analysis revealed many of the proteins that function

277 in inflammatory signaling and immune response are lower in preterm infants with no infection. A

278 likely explanation for this notable difference is that our research excluded preterm infants with early

279 onset sepsis, and thus represents the state of the cord blood proteome in the absence of infection.

280 Given that treatment of early-onset sepsis is common in very preterm infants, the analysis of cord

281 blood inflammatory proteins may be skewed if one has not accounted for infection.

282 Other types of immune phenotyping have been reported in cord blood across GA. Olin et al. noted 283 differences in both cord blood proteins and decreased neutrophil proportions in preterm compared to 284 term infants. They reported an increase in inflammatory cord blood proteins, attributed to the role of 285 inflammation and infection in preterm birth, but not reflecting gestational norms without infection.¹⁴ Anderson et al. utilized flow cytometry and cytokine assays of cord blood to compare preterm infants 286 (30-34 weeks GA) to full-term infants.²⁴ They found that preterm infants had lower frequencies of 287 monocytes, NK cells, CD8+ T-cells and gamma-delta T-cells than their term full term counterparts. 288 289 There were increased intermediate monocytes, CD4 T cells, Tregs, and transitional B-cells in preterm 290 infants indicating immaturity of the innate immune system and a skewed cellular landscape related to 291 increased susceptibility of preterm infants to bacterial and viral infections. They also noted lower 292 levels of pro-inflammatory cytokines and chemokines in preterm infants, further confirming preterm 293 infants impaired ability to fight off infection. Finally, Peterson et al. applied single-cell 294 immunoprofiling of cord blood for 45 infants (20 preterm) after excluding infants exposed to clinical chorioamnionitis or with active infection.²⁵ The study also controlled for potential other clinical 295 296 confounders, including steroid administration. They found a strong relationship between GA and the 297 neonatal immune profile at birth. Specifically, increasing GA was associated with a progressive 298 increase in the ligand-specific responsiveness to immune system stimulation. This finding aligns with 299 our finding of increased cell-signaling, calcium binding, and immune response proteins with later 300 gestational age. Our work supports the conclusion that decreased antigen- and cytokine-specific

301 immune responses may contribute to preterm infant susceptibility to infection.

302 Furthermore, differences in proteins across GA may provide insight into underlying pathophysiology 303 and risk of pathology. Functional analysis identified several pathways associated with increased

304 abundance of proteins that are implicated in vascular development, lipid metabolism, smooth muscle

- 305 proliferation, insulin-like growth factor regulation, and the matrisome. For example, afamin, an anti-306 inflammatory protein previously hypothesized to be a hallmark of detrimental oxidative stress and
- 307 related to retinopathy of prematurity, is less abundant in the cord blood of preterm infants.¹⁶ The
- 308 process of in utero development represents a complex and dynamic system between the pregnant
- 309 person and fetus. Through this study of neonates born from 25-42 weeks GA, we aim to help
- 310 establish the baseline state of the developmental continuum.

The strengths of this study include: 1) the analysis of cord blood proteomics on a large sample size across the GA spectrum; 2) precise clinical categorization and consideration of covariates that may

- 313 impact the cord blood proteome including exclusion of infants with early onset infection and
- adjustment for labor, preeclampsia, and sex; and 3) careful methodologic and data normalization,
- 315 both in design and analysis of discovery mass spectrometry proteomics (distribution and
- 316 normalization across batches, pooled control, addressing missingness). Additionally, functional
- 317 pathway analysis strengthens our ability to parse key pathways of relevance and provide validation
- 318 through the demonstration of known GA-related differences in hemoglobin and immunoglobulin
- 319 proteins²⁶. Limitations include that mass spectrometry proteomics does not provide absolute
- 320 quantitation of protein, but rather spectral counts and relative abundance. The detectable protein
- 321 abundance reflects the level after potential clearance, degradation, or transport/localization of
- expressed proteins to compartments. For this reason, we highlight relative abundance and levels of proteins rather than using terms akin to protein expression (i.e., "up/down-regulation"). Thus,
- 323 proteins ratie than using terms akin to protein expression (i.e., up/down-regulation). Thus, 324 specific biomarker development warrants quantitative validation methods. Additionally, the cord
- blood specime used in this analysis was intended to be obtained at the time of birth from the
- 326 umbilical vein. However, it is possible that there is some mixing of umbilical arterial and venous
- 327 blood. Prior literature raises questions about mediating cord blood markers by placental clearance
- 328 and whether cord blood proteins may reflect maternal serum. In multiple studies, paired analysis of
- 329 maternal and fetal cord blood biomarkers has shown weak or no correlation.^{27,28}

330 In conclusion, our study utilizing untargeted proteomics has demonstrated that the cord blood

- 331 proteome varies significantly with GA at birth. There are meaningful differences in several pathways,
- including crucial aspects of inflammation and immune response. Future research can apply this
- knowledge of the baseline state to find methods to develop more precise, GA-specific cord blood
- diagnostic markers of short and perhaps long-term²⁹ health and disease.

335 **References**

- Siffel, C., Hirst, A. K., Sarda, S. P., Kuzniewicz, M. W. & Li, D.-K. The clinical burden of
 extremely preterm birth in a large medical records database in the United States: Mortality
 and survival associated with selected complications. *Early human development* 171, 105613
 (2022). https://doi.org/https://doi.org/10.1016/j.earlhumdev.2022.105613
- Manuck, T. A. *et al.* Preterm neonatal morbidity and mortality by gestational age:
 a contemporary cohort. *American journal of obstetrics and gynecology* 215, 103.e101103.e114 (2016). https://doi.org/10.1016/j.ajog.2016.01.004
- 343 3 Ohuma, E. O. *et al.* National, regional, and global estimates of preterm birth in 2020, with
 344 trends from 2010: a systematic analysis. *Lancet* 402, 1261-1271 (2023).
 345 <u>https://doi.org/10.1016/s0140-6736(23)00878-4</u>
- 346 4 Dongen, O. R. E. *et al.* Umbilical Cord Procalcitonin to Detect Early-Onset Sepsis in
 347 Newborns: A Promising Biomarker. *Frontiers in pediatrics* 9, 779663 (2021).
 348 https://doi.org/10.3389/fped.2021.779663
- Mithal, L. B., Palac, H. L., Yogev, R., Ernst, L. M. & Mestan, K. K. Cord Blood Acute Phase
 Reactants Predict Early Onset Neonatal Sepsis in Preterm Infants. *PloS one* 12, e0168677
 (2017). https://doi.org/10.1371/journal.pone.0168677
- Su, H. *et al.* Inflammatory markers in cord blood or maternal serum for early detection of
 neonatal sepsis-a systemic review and meta-analysis. *Journal of perinatology : official journal of the California Perinatal Association* **34**, 268-274 (2014).
 https://doi.org/10.1038/jp.2013.186
- Park, Y. J. *et al.* Immune and Inflammatory Proteins in Cord Blood as Predictive Biomarkers
 of Retinopathy of Prematurity in Preterm Infants. *Investigative ophthalmology & visual science* 60, 3813-3820 (2019). <u>https://doi.org/10.1167/iovs.19-27258</u>
- Soti, A. L. *et al.* Can biomarkers in umbilical cord blood predict atopic disease at school age?
 Pediatric research 89, 389-392 (2021). <u>https://doi.org/10.1038/s41390-019-0686-z</u>
- Jiang, C. H. *et al.* Metabolic Profiling Revealed Prediction Biomarkers for Infantile
 Hemangioma in Umbilical Cord Blood Sera: A Prospective Study. *J Proteome Res* 21, 822832 (2022). <u>https://doi.org/10.1021/acs.jproteome.1c00430</u>
- Mestan, K. *et al.* Cord blood biomarkers of the fetal inflammatory response. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 22, 379-387 (2009). https://doi.org/10.1080/14767050802609759
- Letunica, N. *et al.* The use of proteomics for blood biomarker research in premature infants: a
 scoping review. *Clin Proteomics* 18, 13 (2021). <u>https://doi.org/10.1186/s12014-021-09316-y</u>
- Law, K. P., Han, T. L., Tong, C. & Baker, P. N. Mass spectrometry-based proteomics for pre eclampsia and preterm birth. *International journal of molecular sciences* 16, 10952-10985
 (2015). <u>https://doi.org/10.3390/ijms160510952</u>
- Shuken, S. R. An Introduction to Mass Spectrometry-Based Proteomics. *Journal of Proteome Research* 22, 2151-2171 (2023). <u>https://doi.org/10.1021/acs.jproteome.2c00838</u>
- Olin, A. *et al.* Stereotypic Immune System Development in Newborn Children. *Cell* 174, 1277-1292 e1214 (2018). <u>https://doi.org/10.1016/j.cell.2018.06.045</u>

377 15 Geyer, P. E., Holdt, L. M., Teupser, D. & Mann, M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 13, 942 (2017). https://doi.org/10.15252/msb.20156297 378 379 16 Suski, M. et al. Plasma proteome changes in cord blood samples from preterm infants. J 380 Perinatol 38, 1182-1189 (2018). https://doi.org/10.1038/s41372-018-0150-7 381 17 Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized 382 p.p.b.-range mass accuracies and proteome-wide protein quantification. *Nature Biotechnology* 383 26, 1367-1372 (2008). https://doi.org/10.1038/nbt.1511 384 18 Cox, J. et al. Andromeda: A Peptide Search Engine Integrated into the MaxQuant 385 Environment. Journal of Proteome Research 10, 1794-1805 (2011). 386 https://doi.org/10.1021/pr101065j 387 19 Cox, J. et al. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics 13, 2513-2526 388 389 (2014). https://doi.org/10.1074/mcp.M113.031591 390 20 Benjamini, Y. H., Y. Controlling the false Discovery Rate: A Practical and Powerful 391 Approach to Multiple Testing. Journal of the Royal Statistical Society 57, 289-300 (1995). 392 21 Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-393 level datasets. Nat Commun 10, 1523 (2019). https://doi.org/10.1038/s41467-019-09234-6 394 22 Szklarczyk, D. et al. The STRING database in 2023: protein-protein association networks and 395 functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51, 396 D638-d646 (2023). https://doi.org/10.1093/nar/gkac1000 397 23 Wang, X. & Thein, S. L. Switching from fetal to adult hemoglobin. Nat Genet 50, 478-480 398 (2018). https://doi.org/10.1038/s41588-018-0094-z 399 24 Anderson, J. et al. Immune Profiling of Cord Blood From Preterm and Term Infants Reveals 400 Distinct Differences in Pro-Inflammatory Responses. Frontiers in Immunology 12 (2021). 401 https://doi.org/10.3389/fimmu.2021.777927 402 25 Peterson, L. S. et al. Single-Cell Analysis of the Neonatal Immune System Across the 403 Gestational Age Continuum. Frontiers in Immunology 12 (2021). 404 https://doi.org/10.3389/fimmu.2021.714090 405 26 Herkner, K. R. et al. Pediatric and perinatal reference intervals for immunoglobulin light 406 chains kappa and lambda. Clin Chem 38, 548-550 (1992). 407 27 Blohm, M. E. et al. Cardiovascular biomarkers in paired maternal and umbilical cord blood 408 samples at term and near term delivery. Early human development 94, 7-12 (2016). 409 https://doi.org/https://doi.org/10.1016/j.earlhumdev.2016.01.001 410 28 Sivan, E. et al. Adiponectin in Human Cord Blood: Relation to Fetal Birth Weight and 411 Gender. The Journal of Clinical Endocrinology & Metabolism 88, 5656-5660 (2003). https://doi.org/10.1210/jc.2003-031174 412 413 29 Hansmeier, N., Chao, T. C., Goldman, L. R., Witter, F. R. & Halden, R. U. Prioritization of 414 biomarker targets in human umbilical cord blood: identification of proteins in infant blood 415 serving as validated biomarkers in adults. *Environ Health Perspect* **120**, 764-769 (2012). 416 https://doi.org/10.1289/ehp.1104190 417

418 Acknowledgments

- 419 The authors would like to acknowledge Erin Cullather, BS; Paul Martin Thomas, PhD; Aaron
- 420 Hamvas, MD; and Thomas Shanley, MD for their support toward this work. Proteomics services
- 421 were performed by the Northwestern Proteomics Core Facility, generously supported by NCI CCSG
- 422 P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center, instrumentation award
- 423 (S10OD025194) from NIH Office of Director, and the National Resource for Translational and
- 424 Developmental Proteomics supported by P41 GM108569.

425 Author Contributions

- 426 LBM: conceptualization, methodology, data curation, analysis, funding acquisition, writing original
- 427 draft. B-KC and YG: methodology, investigation, data curation, writing review & editing. DS, NL,
- 428 TL-H and JFH: methodology, data curation, formal analysis, visualization, writing review &
- 429 editing. SO and NJR: methodology, investigation, writing review & editing. WAG:
- 430 conceptualization, methodology, supervision, writing review & editing. KM: conceptualization,
- 431 methodology, data curation, supervision, writing review & editing. PCS: conceptualization,
- 432 methodology, data curation, supervision, writing review & editing, funding acquisition. All authors
- 433 contributed to the article and approved the submitted version.

434 Data Availability Statement

- 435 The original contributions presented in the study are included in the article/supplementary material,
- 436 further inquiries can be directed to the corresponding author/s. The raw data supporting the
- 437 conclusions of this article will be made available by the authors, without undue reservation and is
- 438 also available on Proteome Xchange Consortium via the PRIDE partner repository (dataset
- 439 PXD051974).

440 **Conflicts of Interest**

- 441 JFH has received research support, paid to Northwestern University, from Gilead Sciences, and is a
- 442 paid consultant for Merck. The authors declare that the research was conducted in the absence of any
- 443 commercial or financial relationships that could be construed as a potential conflict of interest.

444 Funding

- 445 This work was supported by funding from the NIH (NIAID K23AI139337 to LBM and NHLBI
- 446 K23HL093302 to KGM), Gerber Foundation, Friends of Prentice, and Thrasher Research Fund.
- 447 Additional support was provided by Northwestern University Clinical and Translational Sciences
- 448 Institute (UL1TR001422), Perinatal Origins of Disease Research Program at Lurie Children's, and
- the NUCord Biorepository. Salary support for JFH and TL-H was provided by NIH/NIAID grants
- 450 (R21AI163912, R01AI165236, R01AI150455, R01AI150998, and U19AI135964) and additional
- 451 institutional support for the Center for Pathogen Genomics and Microbial Evolution. The funding
- 452 sources had no role in the study design, data collection, analysis, interpretation, or writing of the
- 453 report.
- 454
- 455

456 Ethics Statement

- 457 Northwestern University and Lurie Children's Institutional Review Boards reviewed and approved
- 458 the studies involving human participants (Northwestern STU00201858, Lurie IRB 2018-2145). The
- 459 patients/participants provided their written informed consent to participate in this study.
- 460

461 Figures:



463Figure 1. Total protein concentration in each plasma sample. Box and whisker plot of protein464concentration (ug/uL) distribution across gestational age (GA) categories. The lower and upper ends465of each box correspond to the 25th and 75th percentiles for a given group [shaded area is the466interquartile range (IQR)]. The black line in each box is the median. The whiskers represent the467largest and smallest observed data points that are no further than +/-1.5 times the IQR, respectively.468Points outside of the boundary of the whiskers are outliers. Kruskal-Wallis across GA categories469p<0.0001.</td>

470



471

472 **Figure 2. Representative plots of relative protein abundance by gestational age.** The scatter

473 plots show the observed values by sex of newborn. The blue line and shaded blue show the fitted

474 linear model and 95% confidence interval (CI) of the association respectively. The purple dashed line

475 shows a loess smoothed line of the association, and the 95% CI is the shaded gray region (most

476 appeared approximately linear). A) Plasminogen model included n=74 samples. B) Alpha-fetoprotein



478





488

489 Figure 4. Functional enrichment analysis of proteins in neonatal cord blood that change over

490 gestational age. A) Heatmap of the protein Z-scores detected in neonatal cord blood samples

- 491 arranged by gestational age from left to right. Proteins are grouped top to bottom by hierarchical
- 492 clustering. Functional enrichment analysis and protein-protein interaction networks of proteins
- 493 significantly **B**) decreased or **C**) increased over gestational age are shown below. Network nodes are
- 494 shaded by abundance change over gestational age with edge width reflecting protein-protein
- 495 interaction confidence. Significantly enriched pathways are highlighted in colored bar charts to the
- 496 left; each protein that maps to the identified pathways is indicated by a color-matched box beneath
- the network node.

498	Table 1. Demographics and clinical covariates

n=150	Patients n (%)
Gestational age weeks median (IQR)	33.7 (29.6-37.5)
25-28	17 (11%)
29-32	43 (29%)
33-36	50 (33%)
≥37	40 (27%)
Infant sex (female)	77 (51%)
Labor and delivery	
vaginal with labor	77 (51%)
caesarean with labor	42 (28%)
caesarean without labor	31 (21%)
Preeclampsia	34 (23%)
Multiple gestation	44 (29%)
Clinical chorioamnionitis	1 (0.7%)